![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
---|---|
Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
ClinicalTrials.gov Identifier: | NCT00236509 |
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg taken daily) compared with placebo in the prevention of migraine.
Condition | Intervention | Phase |
---|---|---|
Common Migraine Headache Migraine Classic Migraine |
Drug: topiramate |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine |
Estimated Enrollment: | 480 |
Study Start Date: | December 2000 |
Estimated Study Completion Date: | September 2002 |
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the effectiveness and safety of three different doses of topiramate (50mg, 100mg, and 200mg daily) in migraine prophylaxis. The study consists of five phases: baseline (determination of whether patients meet the eligibility criteria and tapering of any migraine medication patients are already taking); initial titration and double-blind phase (8 weeks) which begins with 25 mg/daily increasing to the assigned (50, 100, 200 mg/day topiramate); followed by a maintenance period at the target dose (18 weeks); tapering transition phase (up to 7 weeks); and open-label extension up to 6 months (to a maximum topirmate dose of 1600 mg/day); doses are adjusted to maximize effectiveness and minimize side effects. The primary study hypothesis is that one or more of the three doses of topiramate (50, 100, 200 mg/day) will be superior to placebo in the prophylaxis of migraine based on the change in monthly (28 day) migraine period rate from the prospective baseline period to the double-blind phase and that topiramate treatment is well tolerated.
During the titration period (8 weeks), doses are increased to target dose of daily topiramate (50 milligrams[mg], 100, or 200mg) or placebo, taken twice daily by mouth. Doses are continued for 18 weeks, adjusted over 7 weeks, and continued for up to 6 months during the Open-Label Extension.
Ages Eligible for Study: | 12 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Study ID Numbers: | CR002254 |
Study First Received: | October 7, 2005 |
Last Updated: | May 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00236509 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Headache Prophylaxis Migraine |
Common Migraine Topiramate Classic Migraine |
Central Nervous System Diseases Pain Headache Disorders, Primary Brain Diseases Neuroprotective Agents Headache Disorders Anti-Obesity Agents Signs and Symptoms |
Basilar Artery Migraines Migraine Disorders Headache Neurologic Manifestations Topiramate Migraine with Aura Anticonvulsants Migraine without Aura |
Physiological Effects of Drugs Nervous System Diseases Central Nervous System Diseases Pain Headache Disorders, Primary Brain Diseases Protective Agents Neuroprotective Agents Pharmacologic Actions Headache Disorders Anti-Obesity Agents |
Signs and Symptoms Migraine Disorders Therapeutic Uses Headache Neurologic Manifestations Topiramate Migraine with Aura Central Nervous System Agents Anticonvulsants Migraine without Aura |